Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hexavalent reassortant rotavirus attenuated live vaccine
- Development stage
- Phase 2
- Lead developer
- Sinovac Biotech
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
A live attenuated, oral **hexavalent rotavirus vaccine** developed using **reassortant rotavirus strains** derived to cover the six predominant global rotavirus serotypes: G1, G2, G3, G4, G9, and P1A[8]. The vaccine is designed to provide broad-spectrum protection against rotavirus gastroenteritis. It is currently in phase I/II clinical development, with trials evaluating safety, tolerability, and immunogenicity in infants, children, and adults. The vaccine is manufactured using Vero cells and is administered orally in three doses, 28 days apart. The vaccine is intended to address the broad genetic diversity of rotavirus globally and is under development to improve global immunization coverage against severe gastroenteritis caused by rotavirus[2][3][9].
- Other names
- oral hexavalent reassortant rotavirus attenuated live vaccinehexavalent reassortant rotavirus vaccine live oral vero cell
Beyond the preview
Go deeper on hexavalent reassortant rotavirus attenuated live vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hexavalent reassortant rotavirus attenuated live vaccine.